. 2019 Feb 12;20(1):13. doi: 10.1186/s10194-019-0964-5

Table 2.

Total and disease specific visits and sick-leave days of migraine patients and controls

HCRU and sick leaves	Control	G43*, prim. cohort¹	G43*, primary cohort
			Prophylactic	Acute	No prescr.²	BT treated	BT untreated³	Prophylactic treatment line⁴
			Prophylactic	Acute	No prescr.²	BT treated	BT untreated³	0	1	2	≥3
N	17,623	17,623	2199	6525	8899	53	17,570	15,424	1767	334	98
Patient-years	76,804	51,397	7033	17,408	26,955	212	51,184	44,363	5435	1209	390
Average follow-up time per patient (years)	4.4	2.8	3.2	2.7	3.0	4.01	2.91	2.9	3.1	3.6	4.0
Visits
total	649,362	739,803	129,616	261,872	348315*	6480	733323*	610,187	96,241	23,153	10222*
per patient	36.9	42.0*	58.9	40.1	39.1*	122.3	41.7*	39.6	54.5	69.3	104.3*
per patient-year	8.5	14.4*	18.4	15.0	12.9*	30.5	14.3*	13.8	17.7	19.2	26.2*
G43* visits
total		59,937	16,667	23,013	20257*	1862	58075*	43,270	10,597	3729	2341*
per patient		3.4	7.6	3.5	2.3*	35.1	3.3*	2.8	6	11.2	23.9*
per patient-year		1.2	2.4	1.3	0.8*	8.8	1.1*	1.0	2.0	3.1	6.0*
Sick leave days
total	742,162	902,454	158,092	302,586	441776*	7845	894609*	744,362	117,207	29,026	11859*
per patient	42.1	51.2*	71.9	46.4	49.6*	148.0	50.9*	48.3	66.3	86.9	121.0*
per patient-year	9.7	17.6*	22.5	17.4	16.4*	37.0	17.5*	16.8	21.6	24.0	30.4*
G43* sick leave days
total		40,432	14,476	12,384	13572*	2529	37903*	25,956	8265	3613	2598*
per patient		2.3	6.6	1.9	1.5*	47.7	2.2*	1.7	4.7	10.8	26.5*
per patient-year		0.8	2.1	0.7	0.5*	11.9	0.7*	0.6	1.5	3.0	6.7*
Sick leave periods
total		126,816	19,583	45,800	61433*	907	125909*	107,233	14,576	3551	1456*
per patient		7.2	8.9	7.0	6.9*	17.1	7.2*	7.0	8.3	10.6	14.9*
per patient-year		2.5	2.8	2.6	2.3*	4.3	2.5*	2.4	2.7	2.9	3.7*
G43 sick leave periods
total		12,362	2776	4754	4832*	260	12102*	9586	1750	626	400*
per patient		0.7	1.5	0.7	0.5*	4.9	0.7*	0.6	1.0	1.9	4.1*
per patient-year		0.20	0.39	0.27	0.18 *	1.22	0.24*	0.22	0.32	0.52	1.03*

BT botulinum toxin; Significance indicated between 1: controls and G43* primary cohort; 2: prophylactic, acute and no migraine prescription groups; 3: Botulinum toxin treated and untreated patients; 4: between prophylactic treatment lines

*p < 0.001